State Street’s Orexigen Therapeutics, Inc. OREX Stock Holding History

State Street’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-8,136	Closed	-$35K	–	3694
2016 Q2	$35K	Sell	8,136 -157,716	-95%	-$713K	﹤0.01%	3619
2016 Q1	$932K	Sell	165,852 -1,183	-0.7%	-$15.4K	﹤0.01%	3234
2015 Q4	$2.87M	Sell	167,035 -1,011,037	-86%	-$24.1M	﹤0.01%	2840
2015 Q3	$24.9M	Buy	1,178,072 +434,796	+58%	+$14.9M	﹤0.01%	1608
2015 Q2	$36.8M	Buy	743,276 +246,658	+50%	+$14.7M	﹤0.01%	1447
2015 Q1	$38.9M	Buy	496,618 +23,683	+5%	+$1.47M	﹤0.01%	1386
2014 Q4	$28.7M	Sell	472,935 -6,122	-1%	-$308K	﹤0.01%	1532
2014 Q3	$20.4M	Buy	479,057 +65,068	+16%	+$3.49M	﹤0.01%	1734
2014 Q2	$25.6M	Sell	413,989 -9,910	-2%	-$576K	﹤0.01%	1642
2014 Q1	$27.6M	Buy	423,899 +6,396	+2%	+$433K	﹤0.01%	1538
2013 Q4	$23.5M	Sell	417,503 -3,174	-0.8%	-$178K	﹤0.01%	1633
2013 Q3	$25.8M	Buy	420,677 +80,567	+24%	+$5.46M	﹤0.01%	1545
2013 Q2	$19.9M	Buy	+340,110	New	+$20.9M	﹤0.01%	1634

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street's OREX Position: Q3 2016 in Review

State Street sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2016, closing a stake of 8,136 shares — an estimated $35K sold.

State Street first reported a position in OREX in Q2 2013 and held it in 13 quarters. The position peaked at $38.9M in Q1 2015. 55 funds tracked by Wall St. Rank hold OREX as of Q3 2016.

State Street reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
State Street sold 8,136 Orexigen Therapeutics, Inc. shares in Q3 2016, an estimated $35K.
State Street first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 13 quarters.
State Street's Orexigen Therapeutics, Inc. position peaked at $38.9M in Q1 2015.
55 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2016.

Based on State Street's 13F filing for Q3 2016, filed 14 Nov 2016.